SOX30 confers a tumor suppressive effect in acute myeloid leukemia through inactivation of Wnt/β-catenin signaling
Authors:
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Molecular and Cellular Probes
- Vol. 52, 101578
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- An update of current treatments for adult acute myeloid leukemiaBlood, 2016
- SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AMLScientific Reports, 2015
- High expression of SOX30 is associated with favorable survival in human lung adenocarcinomaScientific Reports, 2015
- SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancerOncogene, 2014
- Sox proteins: regulators of cell fate specification and differentiationDevelopment, 2013
- The SOX family of genes in cancer development: biological relevance and opportunities for therapyExpert Opinion on Therapeutic Targets, 2012
- Characterization, phylogeny, alternative splicing and expression of Sox30 geneBMC Molecular Biology, 2010
- Proliferation and bone marrow engraftment of AML blasts is dependent on β‐catenin signallingBritish Journal of Haematology, 2010
- Leukaemogenesis: more than mutant genesNature Reviews Cancer, 2010
- The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemiaLeukemia, 2007